{"groups":[{"description":"Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.","id":"FG000","title":"Tadalafil"},{"description":"Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"12"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"12"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"13"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"23"}],"type":"Assessment outside of Time Frame"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"121"}],"type":"STARTED"},{"achievements":[{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG000","numSubjects":"80"},{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG001","numSubjects":"61"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"60"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}